Lipolysis-stimulated lipoprotein receptor is involved in fatty acid binding protein 4-mediated prostate cancer cell growth in bone

  • 0Department of Anatomy and Cell Biology, Faculty of Pharmacy, Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.

|

|

Summary

This summary is machine-generated.

Fatty acid binding protein 4 (FABP4) promotes prostate cancer progression. Its binding with lipolysis-stimulated lipoprotein receptor (LSR) activates Akt signaling, impacting tumor growth in the bone microenvironment.

Area Of Science

  • Oncology
  • Molecular Biology
  • Endocrinology

Background

  • Obesity-associated adipokines, like FABP4, are linked to prostate cancer malignancy and mortality.
  • Previous research established FABP4's role in promoting prostate cancer cell growth and invasion.

Purpose Of The Study

  • To identify novel binding partners of FABP4 involved in prostate cancer progression.
  • To elucidate the molecular mechanisms by which FABP4 influences prostate cancer in the bone microenvironment.

Main Methods

  • Investigated the interaction between FABP4 and lipolysis-stimulated lipoprotein receptor (LSR) using prostate cancer cell models.
  • Utilized knockdown techniques (LSR KD) to assess the role of LSR in Akt phosphorylation.
  • Performed intraosseous injections of modified cancer cells in vivo to evaluate tumor growth and markers.
  • Co-cultured prostate cancer cells with bone marrow stromal cells (BMSCs) to study FABP4 secretion.

Main Results

  • Lipolysis-stimulated lipoprotein receptor (LSR) was identified as a novel binding partner for FABP4.
  • FABP4-LSR binding induced Akt phosphorylation; LSR knockdown prevented this activation.
  • LSR knockdown prostate cancer cells exhibited reduced intraosseous tumor size, proliferation (Ki-67), and phospho-Akt levels.
  • Bone marrow stromal cells (BMSCs) secreted FABP4 upon co-culture with prostate cancer cells.

Conclusions

  • FABP4-LSR binding is a critical signaling pathway regulating prostate cancer cell progression.
  • The FABP4-LSR interaction mediates prostate cancer cell signaling within the bone microenvironment.
  • Targeting the FABP4-LSR interaction may offer therapeutic strategies for prostate cancer.